Form 4: Lexaria Bioscience Secretary Acquires Common Shares
Insider Transaction Report
Lexaria Bioscience Corp. Secretary Vanessa Carle purchased 750 common shares at $0.91 per share, increasing her direct ownership.
Summary
- Vanessa Carle, the Secretary of Lexaria Bioscience Corp. (LEXX), acquired common shares of the company.
- The transaction involved the purchase of 750 common shares at a price of $0.91 per share.
- The acquisition took place on July 29, 2025.
- Following this transaction, Ms. Carle directly owns 750 common shares.
- Ms. Carle also holds 75,000 stock options with various exercise prices and expiration dates, ranging from $1.04 to $3.00 per share, and expiring between April 26, 2026, and May 15, 2030.
Sentiment
Score: 7
Explanation: The purchase of shares by a company insider generally indicates positive sentiment and confidence in the company's future performance.
Positives
- A company insider, the Secretary, purchased common shares, which can indicate confidence in the company's future prospects.
Stakeholder Impact
- Shareholders may interpret the insider purchase as a positive signal of management's belief in the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date stock options became exercisable with an exercise price of $3.00. |
| 06/08/2021 | Date stock options became exercisable with an exercise price of $3.00. |
| 09/01/2021 | Date stock options became exercisable with an exercise price of $3.00. |
| 08/29/2022 | Date stock options became exercisable with an exercise price of $2.91. |
| 10/26/2023 | Date stock options became exercisable with an exercise price of $1.15. |
| 04/26/2024 | Date stock options became exercisable with an exercise price of $2.36. |
| 05/15/2025 | Date stock options became exercisable with an exercise price of $1.04. |
| 07/29/2025 | Date of common share acquisition by the reporting person. |
| 07/30/2025 | Date the Form 4 filing was signed. |
Recommendation
holdThe purchase of shares by a company insider, the Secretary, can be interpreted as a positive signal of management's confidence in the company's future prospects. However, the relatively small size of the purchase (750 shares) means it should be considered as one data point among many, rather than a standalone reason for a strong investment action. Investors should consider this alongside other financial performance indicators and market conditions.
Keywords
Lexaria Bioscience, LEXX, insider trading, Form 4, beneficial ownership, stock purchase, corporate secretary
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.